Aviceda Therapeutics is a late clinical-stage biotechnology company that is dedicated to harnessing the potential of immune cells' natural checkpoints. By focusing on the modulation of innate and adaptive immune activity, Aviceda aims to address chronic non-resolving inflammation seen in a wide range of diseases. With a team of experienced professionals, including a Board of Directors, Scientific Advisors, and Clinical Advisors, Aviceda is committed to advancing its pipeline of innovative therapies.

The company's Co-Founder and Chief Executive Officer, Dr. Mohamed Genead, brings over 19 years of expertise in ophthalmology research and development, having successfully launched ophthalmic products globally. Supported by Chief Medical Officer Dr.

David Callanan, who has played a key role in the approval of several ophthalmic drugs, and Chief Development Officer Dr. Tarek S. Hassan, a renowned expert in the field, Aviceda is at the forefront of developing novel treatments that have the potential to revolutionize healthcare